Dual PI3Kα/δ Inhibitor

High remission in refractory FL

An oral small-molecule dual PI3Kα/δ inhibitor achieving high response rates in follicular lymphoma patients who have failed at least two prior lines of therapy, offering a new option for refractory cases.

Wang, Huaqing · Feng, Jifeng · Liu, Yanyan · Qian, Zhengzi · Gao, Da · Ran, Xuehong · Zhou, Hui · Liu, Lihong · Fang, Meiyun · Zhou, Hebing · Huang, Zhenqian · Tao, Shi · Chen, Zhuowen · Su, Liping · Su, Hang · Yang, Yu · Xie, Xiaobao · Wu, Huijing · Sun, Ping · Hu, Guoyu · Liang, Aibin · Li, Zhiming

Signal Transduction and Targeted Therapy 2024

Specifications

Objective response rate
{'zh': '86.6', 'en': '95'} %
完全缓解率
{'zh': '34.2', 'en': ''} %
progression-free survival months
{'zh': '95', 'en': '95'} %
个月缓解持续时间率
{'zh': '51.6', 'en': ''} %